The Hidradenitis Suppurativa drugs in development market research report provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hidradenitis Suppurativa. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued products.

GlobalData tracks 47 drugs in development for Hidradenitis Suppurativa by 41 companies/universities/institutes. The top development phase for Hidradenitis Suppurativa is phase ii with 21 drugs in that stage. The Hidradenitis Suppurativa pipeline has 47 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hidradenitis Suppurativa pipeline products market are: Novartis, Incyte and AbbVie.

The key targets in the Hidradenitis Suppurativa pipeline products market include Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A), Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF), and Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2).

The key mechanisms of action in the Hidradenitis Suppurativa pipeline product include Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Inhibitor with seven drugs in Pre-Registration. The Hidradenitis Suppurativa pipeline products include nine routes of administration with the top ROA being Oral and six key molecule types in the Hidradenitis Suppurativa pipeline products market including Monoclonal Antibody, and Small Molecule.

Hidradenitis Suppurativa overview

Hidradenitis suppurativa (HS) is a chronic skin condition that features pea- to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop in areas where skin rubs together, such as the armpits, groin, between the buttocks, and under the breasts.

For a complete picture of Hidradenitis Suppurativa’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.